Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.49 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.48 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.48 |
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.46 |
| ▸ | CETP | P11597 | 1/20 | 0.45 |
| ▸ | FDPS | P14324 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL339035 | 0.98 | ACE2 (0.46) | ACE2LPAR3LPAR2TRPM8CETP | |
| SCHEMBL339782 | 0.93 | GABBR2 (0.47) | ACE2TRPM8FDPS | |
| SCHEMBL340077 | 0.85 | GCLC (0.43) | ACE2FDPS | |
| Hydrochloric Acid SCHEMBL11590513 | 0.83 | LPAR3 (0.46) | LPAR3LPAR2TRPM8FDPS | |
| SCHEMBL2402598 | 0.78 | GRM3 (0.45) | — | |
| SCHEMBL7821202 | 0.77 | LPAR3 (0.62) | ACE2LPAR3LPAR2FDPS | |
| SCHEMBL338963 | 0.77 | GCLC (0.40) | — | |
| SCHEMBL338990 | 0.77 | GABRR1 (0.38) | ACE2FDPS | |
| SCHEMBL7095448 | 0.76 | LPAR3 (0.71) | LPAR3LPAR2TRPM8CETPFDPS | |
| SCHEMBL968792 | 0.76 | LPAR3 (0.71) | LPAR3LPAR2TRPM8CETPFDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097753-B2 | Mixtures composed or monocarboxy-functionalized dialkylphosphinic acids, their use and a process for their preparation | CLARIANT FINANCE (BVI) LIMITED (VG) | 2012-01-17 | — | — | US | disclosed |
| EP-1832594-B1 | Compounds of mono-carboxyl functionalised dialkylphosphine acid salts, a method for their manufacture and their application | CLARIANT FINANCE BVI LTD (VG) | 2011-05-18 | — | — | EP | disclosed |
| US-20070213436-A1 | Mixtures composed or monocarboxy-functionalized dialkylphosphinic acids, their use and a process for their preparation | CLARIANT INTERNATIONAL LTD | 2007-09-13 | — | — | US | disclosed |
| EP-1832594-A1 | Compounds of mono-carboxyl functionalised dialkylphosphine acid salts, a method for their manufacture and their application | CLARIANT INTERNATIONAL LTD. (CH) | 2007-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213436-A1 | Mixtures composed or monocarboxy-functionalized dialkylphosphinic acids, their use and a process for their preparation | PAH, ALKBH3, FTO | ACE2 4803/4885LPAR3 640/4885LPAR2 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.